In the States
Select a state to learn more
State Activity
2015-2016 Session: Convene: 1/13/15 and Adjourn: 4/15/16
The bill has been signed by Governor Haslam.
Both the House and Senate rescheduled when the bill would come to the floor in each chamber. The bill was on the Senate Calendar for 4/06/15 and is on the House Calendar for 4/08/15.
Knoxville News Sentinel: Jeffrey Patton — Tennesseans deserve patient protections
As a medical professional I only have so much control over outcomes for my patients. I can encourage them to eat healthy, take their prescribed medications and exercise, but that only goes so far. At a certain point the control I have over the health of my patients is no longer up to me. And it usually begins when they walk out the door.
Read more here.
-
Bill Information
Defines an “interchangeable biological product” as a biological product determined to be interchangeable by FDA or a product that has been deemed therapeutically equivalent by FDA.
Directs a prescriber to allow substitution with an interchangeable biological product, unless
—prescriber determines the medical necessity of a prescribed biological product because the biosimilar has previously caused adverse reaction or shown to be ineffective, or there is another clinically-based need; or
—an interchangeable is not available.
Permits the dispensing of an interchangeable biological product in place of the prescribed biologic, provided that:
—the biologic is labeled with the name of the manufacturer;
—pharmacist notifies the patient by noting substitution on the prescription label;
—pharmacist notifies the prescriber within a reasonable time (under HB 572) or 5 days (under SB 984), electronically if possible, (and by other means if not), except when there is no FDA-approved interchangeable biosimilar or the prescription is a refill that is unchanged from the prior filling; and
—pharmacist retains record of biologic products dispensed.
Establishes that a pharmacist who substitutes a biosimilar is not subject to greater liability than would be incurred in filling the biologic prescription.
The requirements do not apply to inpatients of a hospital, nursing home, or an assisted-care living facility. Notification and communication requirements do not apply to vaccines.
Directs the Board to maintain on its website a list of approved interchangeable products.
(SB 984 only) Clarifies with regard to electronic communication from pharmacist to prescriber, that, if Tennessee mandates electronic medical records, the electronic notification would not be required until the appropriate system is in place.
-
Archive
ASBM Presents to Nashville Pharmacy Students, Healthcare Practitioners
May 20, 2016
On Wednesday, June 15th, ASBM presented a one-hour educational program entitled “Biosimilars: New Choices, New Challenges” at TriStar Centennial Medical Center in Nashville, TN. Tristar Centennial educates pharmacy students from Belmont University, Lipscomb University, Murray State University, and the University of Tennessee, and the audience was comprised of 20 pharmacy students from these schools as well as nurse-practitioners […]
ASBM Presents to Nashville Pharmacy Students, Healthcare Practitioners
May 20, 2016
On Wednesday, June 15th, ASBM presented a one-hour educational program entitled “Biosimilars: New Choices, New Challenges” at TriStar Centennial Medical Center in Nashville, TN. Tristar Centennial educates pharmacy students from Belmont University, Lipscomb University, Murray State University, and the University of Tennessee, and the audience was comprised of 20 pharmacy students from these schools as well as nurse-practitioners […]
July 13, 2011
East Tennessee Center for Clinical Research Nashville Technology Council Office of Governor Bill Haslam Tennessee Biotechnology Association Tennessee Department of Health Tennessee General Assembly Tennessee House of Representatives Tennessee Medical Association Tennessee State Senate Tennessee Technology Development Corporation Vanderbilt University Office of Technology Transfer and Enterprise Development
July 13, 2011
East Tennessee Center for Clinical Research Nashville Technology Council Office of Governor Bill Haslam Tennessee Biotechnology Association Tennessee Department of Health Tennessee General Assembly Tennessee House of Representatives Tennessee Medical Association Tennessee State Senate Tennessee Technology Development Corporation Vanderbilt University Office of Technology Transfer and Enterprise Development
Life Sciences Tennessee Meeting Report – 2010
July 13, 2011
Thanks to the more than 110 people representing a broad cross section of Tennessee’s life sciences industry who attended our Annual Meeting. The meeting brought education and dialogue from many life science CEOs, venture capitalists, tech transfer experts, students, professors and service providers including life science real estate representatives, attorneys and laboratory suppliers. Read More
Life Sciences Tennessee Meeting Report – 2010
July 13, 2011
Thanks to the more than 110 people representing a broad cross section of Tennessee’s life sciences industry who attended our Annual Meeting. The meeting brought education and dialogue from many life science CEOs, venture capitalists, tech transfer experts, students, professors and service providers including life science real estate representatives, attorneys and laboratory suppliers. Read More
Tennessee Biotechnology Profile
July 13, 2011
Tennessee has more than 5 percent of national employment and a specialized concentration in the agricultural feedstock and chemicals subsector (location quotient of 2.57), which has grown rapidly since 2001. Bioscience academic research and development expenditures have grown by 23.5 percent since 2004 reaching $544 million in 2008, with nearly equal shares in medical and […]
